MDT-10013(MDT-10013) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

神经系统疾病

在研适应症-

非在研适应症

术后疼痛

原研机构

Medtronic Plc

在研机构-

非在研机构

Medtronic Spinal & Biologics Europe

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 MDT-10013 相关的临床试验

NCT02263222 / Withdrawn临床2期

A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty

This is an open-label dose-escalating study to evaluate the tolerability and systemic exposure of MDT-10013 in men and women at least 18 years of age who are undergoing primary unilateral TKA.

开始日期2016-02-01

申办/合作机构

Medtronic Spinal & Biologics Europe

NCT02077140 / Completed临床2期

A Phase II, Dose-escalating, Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetic Profile of MDT-10013 Versus Standard of Care in the Treatment of Acute Postoperative Pain Following Bunionectomy

The purpose of this study is to evaluate the efficacy and safety of MDT-10013 in men and women 18 to 80 years of age who are undergoing bunionectomy. The primary objective is to determine the analgesic efficacy of MDT-10013 compared with standard of care in the treatment of acute postoperative pain after subjects undergo bunionectomy.

开始日期2014-02-01

申办/合作机构

Medtronic Spinal & Biologics Europe

100 项与 MDT-10013 相关的临床结果

登录后查看更多信息

100 项与 MDT-10013 相关的转化医学

登录后查看更多信息

100 项与 MDT-10013 相关的专利（医药）

登录后查看更多信息

100 项与 MDT-10013 相关的药物交易

登录后查看更多信息